Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically ...

Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for PluvictoTM plus hormone therapy versus hormone therapy alone ...

Novartis announced topline results from a pre-specified interim analysis of the phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT) 3. Almost all mHSPC patients ultimately progress to metastatic ...

Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically ...